Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257979 | 0.84 | MRGPRX1 (0.44) | SLC6A2SLC6A4SLC6A3F10ACHE | |
| SCHEMBL11294787 | 0.82 | FFAR4 (0.43) | SLC6A2SLC6A4SLC6A3F10ACHE | |
| SCHEMBL10269468 | 0.82 | FFAR1 (0.43) | SLC6A2SLC6A4SLC6A3F10ACHE | |
| SCHEMBL27519440 | 0.82 | ACHE (0.42) | SLC6A2SLC6A4SLC6A3F10ACHE | |
| SCHEMBL12261280 | 0.81 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3F10ACHE | |
| SCHEMBL30564845 | 0.79 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3F10FFAR4 | |
| SCHEMBL17606035 | 0.79 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3F10FFAR4 | |
| SCHEMBL19317569 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3F10MRGPRX1 | |
| SCHEMBL7938427 | 0.79 | MAPT (0.46) | SLC6A2SLC6A4SLC6A3ACHEHTR1A | |
| SCHEMBL3179032 | 0.77 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3ACHEHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253592-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| WO-2016042453-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253592-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SLC6A3, SLC6A2, SLC6A19 | SLC6A2 2/4885SLC6A4 12/4885SLC6A3 1/4885 |
| US-20170253615-A1 | Spirocyclic derivatives | SLC6A3, SLC10A1, ABCB11 | SLC6A2 4/4885SLC6A4 17/4885SLC6A3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.